International Journal of Endocrinology and Metabolism

Published by: Kowsar

Clinical Trials in Management of Anaplastic Thyroid Carcinoma; Progressions and Set Backs: A Systematic Review

Behrouz Salehian 1 , * , Simon Y Liem 1 , Hoda Mojazi Amiri 1 and Ellie Maghami 2
Authors Information
1 Department of Diabetes, Endocrinology and Metabolism, Duarte, United States
2 Department of Surgical Oncology, Division of Head and Neck Surgery, Duarte, United States
Article information
  • International Journal of Endocrinology and Metabolism: 17 (1); e67759
  • Published Online: January 13, 2019
  • Article Type: Review Article
  • Received: February 20, 2018
  • Revised: December 2, 2018
  • Accepted: December 24, 2018
  • DOI: 10.5812/ijem.67759

To Cite: Salehian B, Liem S Y, Mojazi Amiri H, Maghami E. Clinical Trials in Management of Anaplastic Thyroid Carcinoma; Progressions and Set Backs: A Systematic Review, Int J Endocrinol Metab. Online ahead of Print ; 17(1):e67759. doi: 10.5812/ijem.67759.

Abstract
Copyright © 2019, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Methods
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Sun XS, Sun SR, Guevara N, Fakhry N, Marcy PY, Lassalle S, et al. Chemoradiation in anaplastic thyroid carcinomas. Crit Rev Oncol Hematol. 2013;86(3):290-301. doi: 10.1016/j.critrevonc.2012.10.006. [PubMed: 23218594].
  • 2. Ishiwata I, Ono I, Kiguchi K, Ishiwata C, Soma M, Ishikawa H. Establishment and characterization of a human thyroid carcinoma cell line (HOTHC) producing colony stimulating factor. Hum Cell. 2005;18(3):163-9. doi: 10.1111/j.1749-0774.2005.tb00007.x. [PubMed: 17022149].
  • 3. Narimatsu M, Nagayama Y, Akino K, Yasuda M, Yamamoto T, Yang TT, et al. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. J Clin Endocrinol Metab. 1998;83(10):3668-72. doi: 10.1210/jcem.83.10.5160. [PubMed: 9768682].
  • 4. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group . Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6(7). e1000097. doi: 10.1371/journal.pmed.1000097. [PubMed: 19621072]. [PubMed Central: PMC2707599].
  • 5. Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, Suzuki S. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg. 2012;36(6):1247-54. doi: 10.1007/s00268-012-1437-z. [PubMed: 22311136].
  • 6. Siironen P, Hagstrom J, Maenpaa HO, Louhimo J, Heikkila A, Heiskanen I, et al. Anaplastic and poorly differentiated thyroid carcinoma: Therapeutic strategies and treatment outcome of 52 consecutive patients. Oncology. 2010;79(5-6):400-8. doi: 10.1159/000322640. [PubMed: 21455012].
  • 7. Mohebati A, Dilorenzo M, Palmer F, Patel SG, Pfister D, Lee N, et al. Anaplastic thyroid carcinoma: A 25-year single-institution experience. Ann Surg Oncol. 2014;21(5):1665-70. doi: 10.1245/s10434-014-3545-5. [PubMed: 24554064].
  • 8. Sugitani I, Hasegawa Y, Sugasawa M, Tori M, Higashiyama T, Miyazaki M, et al. Super-radical surgery for anaplastic thyroid carcinoma: A large cohort study using the Anaplastic Thyroid Carcinoma Research Consortium of Japan database. Head Neck. 2014;36(3):328-33. doi: 10.1002/hed.23295. [PubMed: 23729360].
  • 9. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid. 2000;10(7):587-94. doi: 10.1089/thy.2000.10.587. [PubMed: 10958311].
  • 10. Onoda N, Sugino K, Higashiyama T, Kammori M, Toda K, Ito K, et al. The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients: A nationwide prospective study. Thyroid. 2016;26(9):1293-9. doi: 10.1089/thy.2016.0072. [PubMed: 27484330].
  • 11. Chemotherapy Committee, The Japanese Society of Thyroid Surgery. Intensive chemotherapy for anaplastic thyroid carcinoma: combination of cisplatin, doxorubicin, etoposide and peplomycin with granulocyte granulocyte colony-stimulating factor support. Jpn J Clin Oncol. 1995;25(5):203-7. doi: 10.1093/oxfordjournals.jjco.a039778. [PubMed: 7474408].
  • 12. Kwon J, Kim BH, Jung HW, Besic N, Sugitani I, Wu HG. The prognostic impacts of postoperative radiotherapy in the patients with resected anaplastic thyroid carcinoma: A systematic review and meta-analysis. Eur J Cancer. 2016;59:34-45. doi: 10.1016/j.ejca.2016.02.015. [PubMed: 27014798].
  • 13. Pezzi TA, Mohamed ASR, Sheu T, Blanchard P, Sandulache VC, Lai SY, et al. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. Cancer. 2017;123(9):1653-61. doi: 10.1002/cncr.30493. [PubMed: 28026871]. [PubMed Central: PMC5906051].
  • 14. Mitchell G, Huddart R, Harmer C. Phase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol. 1999;50(1):33-8. doi: 10.1016/S0167-8140(98)00102-9. [PubMed: 10225555].
  • 15. Tanaka K, Sugitani I, Fujimoto Y. A novel chemo-radiotherapy with low-dose daily cisplatin, 5-fluorouracil and doxorubicin for anaplastic thyroid carcinoma: A preliminary report. Jpn J Clin Oncol. 2011;41(9):1074-8. doi: 10.1093/jjco/hyr095. [PubMed: 21791572].
  • 16. Onoda N, Kashiwagi S, Noda S, Kawajiri H, Takashima T, Ishikawa T, et al. High efficacy of chemoradiation therapy sensitized by weekly docetaxel for anaplastic thyroid cancer. Anticancer Res. 2013;33(8):3445-8. [PubMed: 23898117].
  • 17. Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: A single-institution experience using aggressive multimodal therapy. Thyroid. 2011;21(1):25-30. doi: 10.1089/thy.2010.0220. [PubMed: 21162687].
  • 18. Prasongsook N, Kumar A, Chintakuntlawar AV, Foote RL, Kasperbauer J, Molina J, et al. Survival in response to multimodal therapy in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2017;102(12):4506-14. doi: 10.1210/jc.2017-01180. [PubMed: 29029287].
  • 19. Orita Y, Sugitani I, Amemiya T, Fujimoto Y. Prospective application of our novel prognostic index in the treatment of anaplastic thyroid carcinoma. Surgery. 2011;150(6):1212-9. doi: 10.1016/j.surg.2011.09.005. [PubMed: 22136842].
  • 20. Williams R. Discontinued in 2013: Oncology drugs. Expert Opin Investig Drugs. 2015;24(1):95-110. doi: 10.1517/13543784.2015.971154. [PubMed: 25315907].
  • 21. Mooney CJ, Nagaiah G, Fu P, Wasman JK, Cooney MM, Savvides PS, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid. 2009;19(3):233-40. doi: 10.1089/thy.2008.0321. [PubMed: 19265494]. [PubMed Central: PMC2913806].
  • 22. Shimazaki N, Togashi N, Hanai M, Isoyama T, Wada K, Fujita T, et al. Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model. Eur J Cancer. 2008;44(12):1734-43. doi: 10.1016/j.ejca.2008.04.016. [PubMed: 18511262].
  • 23. Krajewska J, Handkiewicz-Junak D, Jarzab B. Sorafenib for the treatment of thyroid cancer: An updated review. Expert Opin Pharmacother. 2015;16(4):573-83. doi: 10.1517/14656566.2015.1005601. [PubMed: 25605317].
  • 24. Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 2014;24(2):232-40. doi: 10.1089/thy.2013.0078. [PubMed: 23721245].
  • 25. Murakami H, Ono A, Takahashi T, Onozawa Y, Tsushima T, Yamazaki K, et al. Phase I study of efatutazone, an oral PPARgamma agonist, in patients with metastatic solid tumors. Anticancer Res. 2014;34(9):5133-41. [PubMed: 25202104].
  • 26. Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, et al. Efatutazone, an oral PPAR-gamma agonist, in combination with paclitaxel in anaplastic thyroid cancer: Results of a multicenter phase 1 trial. J Clin Endocrinol Metab. 2013;98(6):2392-400. doi: 10.1210/jc.2013-1106. [PubMed: 23589525]. [PubMed Central: PMC3667260].
  • 27. Savvides P, Nagaiah G, Lavertu P, Fu P, Wright JJ, Chapman R, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid. 2013;23(5):600-4. doi: 10.1089/thy.2012.0103. [PubMed: 23113752]. [PubMed Central: PMC3643255].
  • 28. Bible KC, Suman VJ, Menefee ME, Smallridge RC, Molina JR, Maples WJ, et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab. 2012;97(9):3179-84. doi: 10.1210/jc.2012-1520. [PubMed: 22774206]. [PubMed Central: PMC3431569].
  • 29. Wetzler LM. The role of Toll-like receptor 2 in microbial disease and immunity. Vaccine. 2003;21 Suppl 2:S55-60. doi: 10.1016/S0264-410X(03)00201-9. [PubMed: 12763684].
  • 30. Fukuhara T, Donishi R, Koyama S, Miyake N, Matsuda E, Fujiwara K, et al. Significant amelioration of tracheal stenosis following lenvatinib in a patient who has anaplastic thyroid carcinoma with bronchomediastinal infiltration: A case report. Case Rep Oncol. 2017;10(1):175-81. doi: 10.1159/000457831. [PubMed: 28413394]. [PubMed Central: PMC5346947].
  • 31. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7-13. doi: 10.1200/JCO.2017.73.6785. [PubMed: 29072975]. [PubMed Central: PMC5791845].
  • 32. Food and Drug Administration. FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAF V600E mutation. 2018. Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm606708.htm.
  • 33. Dedecjus M, Tazbir J, Kaurzel Z, Lewinski A, Strozyk G, Brzezinski J. Selective embolization of thyroid arteries as a preresective and palliative treatment of thyroid cancer. Endocr Relat Cancer. 2007;14(3):847-52. doi: 10.1677/ERC-07-0011. [PubMed: 17914113].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments